Feinstein Institute Presents Cerami Award to Oxford University Researcher

Monograph for David J. Weatherall to focus on his research about inherited disorders of hemoglobin to be published in Molecular Medicine

Manhasset, NY – The North Shore-LIJ Health System and Molecular Medicine announced today that the third Anthony Cerami Award in Translational Medicine will be conferred to David J. Weatherall, MD, FRCP, FRS, founder of the Weatherall Institute of Molecular Medicine at Oxford University in England. The award is in recognition of his discoveries in inherited disorders of hemoglobin.

The Cerami award, which includes a $20,000 prize, is conferred semi-annually by the peer-reviewed, open-access journal Molecular Medicine published by the Feinstein Institute Press. A monograph authored by Professor Sir David Weatherall, entitled “A Journey in Science: Early Lessons from the Hemoglobin Field,” will be published online in November in Molecular Medicine.

“The Anthony Cerami Award in Translational Medicine was created to recognize investigators who provided the crucial, early insight and ideas that are the essence of discovery, creating new fields and research trajectories followed by the persistent clinical investigation that ultimately changes how disease is prevented, diagnosed and treated,” said Kevin J. Tracey, MD, president of the Feinstein Institute, editor emeritus of Molecular Medicine and Cerami Award committee member. “Professor Sir David Weatherall’s research over the last 50 years has improved clinical treatment worldwide for disorders relates to hemoglobin. His monograph is a fascinating story encompassing a career in military service in Singapore, schooling in the US, and developing the Institute of Molecular Medicine in England.”

In the monograph, Professor Weatherall describes his experience in the early days of studying inherited disorders of hemoglobin and how many of the lessons learned from this field continue to have implications in molecular medicine. “Any success that the author of this review has had in the field is based on developing a stable team of a few senior scientists with backgrounds both in clinical medicine or molecular biology, together with a constant throughput of excellent young people wishing to be trained in the field,” he said. “In addition, because the hemoglobin disorders are particularly common in some of the poorer tropical countries, it has been equally important to develop partnerships with these countries, not just for carrying out research, but also to help with capacity building for improving programs for the prevention and treatment of these conditions.” He also offered this advice to aspiring scientists: “It is still important for young people to spend some time after receiving their first degree to gain further experience before deciding which particular aspect of the field they wish to pursue and, once they have decided, to follow their line of research intensely and with single-minded enthusiasm, and not to be put off by ill-directed advice by ill-informed mentors.”

“It has been a particular pleasure to receive the Cerami Award in Translational Medicine,” added Professor Weatherall. “Particularly because it is linked to the name of Tony Cerami, whose work I have admired over many years.”

The Feinstein Institute is committed to celebrating the stewardship of the scientific process and imparting that perspective to young scientists. The Feinstein Institute also recognizes that the story behind making a discovery in medicine and healthcare is cherished and should be documented. The goal of the Cerami Award and its associated monographs is to document such innovations and discoveries, so that they can endure and inspire future generations of investigators.

The Anthony Cerami Award in Translational Medicine was made possible made possible by the generosity of the Anthony Cerami, PhD, and Ann Dunne Foundation for World Health. Dr. Cerami’s breakthrough translational work includes the identification of anti-TNF’s potential to treat a number of inflammatory diseases including rheumatoid arthritis, and the development of the HbA1c Diagnostic Test, currently the gold standard for the diagnosis and control of diabetes. He is currently working on a potential treatment of diabetes as CEO of Araim Pharmaceuticals.

About Molecular Medicine

Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by the Feinstein Institute Press. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, visit www.molmed.org.

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson’s disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit www.FeinsteinInstitute.org.

Media Contact:
Terry Lynam, Vice President of Public Relations
(516) 465-2640